143708-33-2

Basic information

• Product Name: 2-(CHLOROMETHYL)-6-METHYL-1,3-BENZOXAZOLE
• Synonyms: 2-(CHLOROMETHYL)-6-METHYL-1,3-BENZOXAZOLE;2-Chloromethyl-6-methyl-benzooxazole;Benzoxazole,2-(chloromethyl)-6-methyl-
• CAS NO: 143708-33-2
• Molecular Formula: C₉H₈ClNO
• Molecular Weight: 181.62
• Mol File: 143708-33-2.mol

Chemical Properties

• Boiling Point: 260.2°Cat760mmHg
• Flash Point: 111.2°C
• Appearance: /
• Density: 1.265g/cm³
• Vapor Pressure: 0.0201mmHg at 25°C
• Refractive Index: 1.599
• CAS DataBase Reference: 2-(CHLOROMETHYL)-6-METHYL-1,3-BENZOXAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(CHLOROMETHYL)-6-METHYL-1,3-BENZOXAZOLE(143708-33-2)
• EPA Substance Registry System: 2-(CHLOROMETHYL)-6-METHYL-1,3-BENZOXAZOLE(143708-33-2)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 143708-33-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(Chloromethyl)-6-methyl-1,3-benzoxazole is used as a building block for the synthesis of various pharmaceutical compounds. Its unique structure and reactivity allow for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, 2-(Chloromethyl)-6-methyl-1,3-benzoxazole serves as a key intermediate in the production of agrochemicals. Its properties contribute to the creation of effective compounds for crop protection and pest control.
Used as a Fluorescent Probe:
2-(Chloromethyl)-6-methyl-1,3-benzoxazole is utilized as a fluorescent probe for detecting metal ions. Its ability to fluoresce in the presence of certain metal ions makes it a valuable tool in analytical chemistry and environmental monitoring.
Investigated for Pharmacological Properties:
Research is being conducted to explore the potential pharmacological properties of 2-(Chloromethyl)-6-methyl-1,3-benzoxazole. Its unique structure may offer new avenues for drug discovery and development in various therapeutic areas.

InChI:InChI=1/C9H8ClNO/c1-6-2-3-7-8(4-6)12-9(5-10)11-7/h2-4H,5H2,1H3

Upstream product

• 2835-98-5 2-Hydroxy-4-methylanilin 
• 74974-54-2 2-chloro-1,1,1-trimethoxyethane 
• 79-04-9 chloroacetyl chloride 

Downstream Products

• 1201041-68-0 (R)-1-(6-methyl-benzooxazol-2-ylmethyl)-3-((S)-2-phenyl-2-piperidin-1-yl-propionyloxy)-1-azonia-bicyclo[2.2.2]octane chloride 
• 1266101-11-4 C₂₈H₂₇ClFN₃O₂ 
• 1266101-12-5 C₂₈H₂₇ClFN₃O₂ 
• 1266101-13-6 C₂₈H₂₈BrN₃O₂ 
• 1266101-14-7 C₂₈H₂₇BrFN₃O₂ 
• 1266101-15-8 C₂₈H₂₇BrFN₃O₂ 
• 1266101-16-9 C₂₉H₂₈F₃N₃O₂ 
• 1195983-12-0 (R)-1-(6-methylbenzooxazol-2-ylmethyl)-3-(1-phenylcycloheptanecarbonyloxy)-1-azoniabicyclo[2.2.2]octane chloride 
• 143708-03-6 5-Ethyl-6-methyl-3-[(6-methyl-benzooxazol-2-ylmethyl)-amino]-1H-pyridin-2-one 

Relevant articles and documents

COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF

The present invention provides a compound having a specific chemical structure and having PDE9A inhibitory activity, or a pharmaceutically acceptable salt thereof. The present invention provides a composition containing the compound or a pharmaceutically acceptable salt thereof. The present invention provides a pharmaceutical use, for treating or preventing PDE9A-related diseases, of the compound according to the present invention, a salt thereof, and a composition containing the compound or salt. The present invention also provides a method for treating or preventing PDE9A-related diseases, the method comprising administering an effective amount of the compound according to the present invention, a salt thereof, or a composition containing the compound or salt to a subject in need of treatment.

1-AZA-BICYCLO [2.2.2] OCTANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS

The invention provides named compounds of formula (I), pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions and their use in therapy.

QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

The invention provides compounds of formula (I) wherein R1, R2, R3, R4, R5, Het1, n, Y and X are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them, a process for preparing pharmaceutical compositions, their use in therapy and intermediates of use in their preparation.